Advanced Cell Technology Files Application for Trial to Treat Dry AMD With Human Embryonic Stem Cells

November 30, 2010

To go along with its recent OK from the FDA to begin treating Stargardt’s disease, a form of juvenile macular degeneration, Advanced Cell Technology announced today that it had filed for a new drug (IND) application to begin a Phase I/II clinical trial using human embryonic stem cells (hESCs) to treat the dry form of age-related macular degeneration, for which, to date, there is no approved treatment. The trial will be a multi-centered effort and will begin with twelve patients to test the safety of using stem cells in humans.

For more on this ground-breaking announcement, affecting some 30 million people worldwide, please see: link

To read about the recent Stargardt’s disease trial, please see:  link




Jump down to form below to submit your own comments

Comments are closed.